Tech Tuesday: Predicting Type 2 diabetes

Share:
A hand holding a looking glass by a lake
Crowdsource Innovation
Get involved with our crowdsourced digital platform to deliver impact at scale

Tech Tuesday is an ongoing series profiling the Forum’s Technology Pioneers. The Tech Pioneers are companies that have been recognized by the Forum for groundbreaking and innovative approaches in tackling some of the world’s most wicked problems. Each week we will showcase some of the 2012 Tech Pioneers. You can learn more about the Technology Pioneer Programme on the Forum’s website.

Tethys Bioscience develops sophisticated biological markers that enable the precise targeting of healthcare resources

Determining which patients will contract a chronic metabolic disease two or three years from now is a constant dilemma for most primary physicians. The doctor has to put extra work into expensive tests that may not really be necessary, and the patient may be burdened with expensive and potentially harmful prescriptions that he does not really need. The solution is to identify the population at risk with much greater precision than has been available until now.

Tethys Bioscience is developing a new generation of biological markers that promise to do just that. One of the company’s first products, PreDx DRS, combines multiple markers with a proprietary algorithm to deliver an unprecedented level of risk stratification in assessing the likelihood that a patient will develop Type 2 diabetes over the next five years. Rapid intervention may be able to keep a patient from ever developing the disease at all. Another Tethys Bioscience test precisely predicts a patient’s vulnerability to fractures from osteoporosis. Both tests are only in the initial phase of a programme intended to extend reliable testing to a broad range of diseases. Tethys Biosciences’ pioneering efforts promise to revolutionize the face of future medicine by focusing scarce resources where they are most needed and alerting patients to future dangers in time for preventative action.

 

Tethys Bioscience
Mickey Urdea, Chairman and Chief Executive Officer
Location: CA, USA
Number of Employees: 102
Year Founded: 2002

Tethys Bioscience
5858 Horton Street, Suite 280
Emeryville, CA 94608
USA
Telephone: +1 510 420 6700
clientservices@tethysbio.com
www.tethysbio.com

Don't miss any update on this topic

Create a free account and access your personalized content collection with our latest publications and analyses.

Sign up for free

License and Republishing

World Economic Forum articles may be republished in accordance with the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Public License, and in accordance with our Terms of Use.

The views expressed in this article are those of the author alone and not the World Economic Forum.

Share:
World Economic Forum logo
Global Agenda

The Agenda Weekly

A weekly update of the most important issues driving the global agenda

Subscribe today

You can unsubscribe at any time using the link in our emails. For more details, review our privacy policy.

About Us

Events

Media

Partners & Members

  • Join Us

Language Editions

Privacy Policy & Terms of Service

© 2024 World Economic Forum